Caption Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Caption Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-34,540	Closed	-$390K	–	1795
2022 Q2	$390K	Buy	+34,540	New	+$694K	0.01%	1127
2022 Q1	–	Sell	-13,750	Closed	-$364K	–	1871
2021 Q4	$364K	Buy	13,750 +250	+2%	+$7.54K	﹤0.01%	1325
2021 Q3	$490K	Sell	13,500 -8,750	-39%	-$344K	0.01%	1202
2021 Q2	$966K	Buy	22,250 +19,750	+790%	+$746K	0.01%	908
2021 Q1	$86K	Buy	+2,500	New	+$99K	﹤0.01%	967
2020 Q4	–	Sell	-7,000	Closed	-$168K	–	1208
2020 Q3	$168K	Buy	+7,000	New	+$172K	﹤0.01%	921

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Caption Management's RIGL Position: Q3 2022 in Review

Caption Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 34,530 shares — an estimated $390K sold.

Caption Management first reported a position in RIGL in Q4 2018 and held it in 4 quarters. The position peaked at $390K in Q2 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

Caption Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Caption Management sold 34,530 Rigel Pharmaceuticals shares in Q3 2022, an estimated $390K.
Caption Management first reported a position in Rigel Pharmaceuticals in Q4 2018 and held it in 4 quarters.
Caption Management's Rigel Pharmaceuticals position peaked at $390K in Q2 2022.
138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.